Effects on the immune system

Handbook of Experimental Pharmacology

Volumn 168, Issue , 2005, Pages 385-423

  Cabral, G A ^a   Staab, A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

B lymphocytes; Cannabinoid receptors; Cannabinoids; Cytokines; Endocannabinoids; Human immunodeficiency virus; Immunity; Infections; Macrophages; Mast cells; Microglia; Natural killer cells; T lymphocytes; THC; Therapeutics

Indexed keywords

EID: 84859047666     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-26573-2_13     Document Type: Article

References (182)

1. Abood ME, Martin BR (1996)Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 39:197-221
2. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M (2003) Short-Term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann Intern Med 139:258-266
3. Arata S, Klein TW, Newton C, Friedman H (1991) Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. Life Sci 49:473-479
4. Arata S, Newton C, Klein T, Friedman H(1992) Enhanced growth of Legionella pneumophila in tetrahydrocannabinol-Treated macrophages. Proc Soc Exp Biol Med 199:65-67
5. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23:2511-2516
6. Ashfaq MK, Watson ES, elSohly HN (1987) The effect of subacute marijuana smoke inhalation on experimentally induced dermonecrosis by S. aureus infection. Immunopharmacol Immunotoxicol 9:319-331
7. Baczynsky WO, Zimmerman AM(1983a) Effects of delta-9- Tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. I. In vivo investigation of the primary and secondary immune response. Pharmacology 26:1-11
8. Baczynsky WO, Zimmerman AM(1983b) Effects of delta-9- Tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacology 26:12-19
9. Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD (1997) Marijuana and cocaine impair alveolar macrophage function and cytokine production.AmJRespir Crit Care Med 156:1606-1613
10. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP (1998) Histopathologic and molecular alterations in bronchial epitheliumin habitualsmokers ofmarijuana, cocaine, and/or tobacco. J Natl Cancer Inst 90:1198-1205
11. Bass R, Engelhard D, Trembovler V, Shohami E (1996) A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. J Infect Dis 173:735-738
12. Berdyshev E, Boichot E, Corbel M, Germain N, Lagente V (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 63:L125-L129
13. Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V (1997) Influence of fatty acid ethanolamides and delta-9-Tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330:231-240
14. Blanchard DK, Newton C, Klein TW, Stewart WE, Friedman H (1986) In vitro and in vivo suppressive effects of delta-9-Tetrahydrocannabinol on interferon production bymurine spleen cells. Int J Immunopharmacol 8:819-824
15. Blevins RD, Dumic MP(1980) The effect of delta-9-Tetrahydrocannabinol on herpes simplex virus replication. J Gen Virol 49:427-431
16. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214:173-180
17. Bradley SG, Munson AE, Dewey WL, Harris LS (1977) Enhanced susceptibility of mice to combinations of delta-9-Tetrahydrocannabinol and live or killed gram-negative bacteria. Infect Immun 17:325-329
18. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ, McCune JM, Abrams DI (2002) Shortterm effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 42:82S-89S
19. Breivogel CS, Griffin G, DiMarzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
20. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A(2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396:141-149
21. Burnette-Curley D, Cabral GA (1995) Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta-9-Tetrahydrocannabinol. Proc Soc Exp Biol Med 210:64-76
22. Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K, Cabral GA (1993) Delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmétte-Guerin-Activated macrophages. Int J Immunopharmacol 15:371-382
23. Cabral GA, Dove Pettit DA (1998) Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83:116-123
24. Cabral GA, Fischer-Stenger K (1994) Inhibition of macrophage inducible protein expression by delta-9-Tetrahydrocannabinol. Life Sci 54:1831-1844
25. Cabral GA, Vasquez R (1991) Effects of marijuana on macrophage function. Adv Exp Med Biol 288:93-105
26. Cabral GA, Vasquez R (1992) Delta-9-Tetrahydrocannabinol suppresses macrophage extrinsic antiherpesvirus activity. Proc Soc Exp Biol Med 199:255-263
27. Cabral GA, Lockmuller JC, Mishkin EM (1986a) Delta-9-Tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc Soc Exp Biol Med 181:305-311
28. Cabral GA, Mishkin EM, Marciano-Cabral F, Coleman P, Harris L, Munson AE(1986b) Effect of delta-9-Tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc Soc Exp Biol Med 182:181-186
29. Cabral GA, McNerney PJ, Mishkin EM (1987a) Interaction of delta-9-Tetrahydrocannabinol with rat B103 neuroblastoma cells. Arch Toxicol 60:438-449
30. Cabral GA, McNerney PJ, Mishkin EM (1987b) Delta-9-Tetrahydrocannabinol inhibits the splenocyte proliferative response to herpes simplex virus type 2. Immunopharmacol Immunotoxicol 9:361-370
31. Caiaffa WT, Vlahov D, Graham NM, Astemborski J, Solomon L, Nelson KE, Munoz A (1994) Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 150:1493-1498
32. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiegue S, Mondière P, Penarier G, Le Fur GL, Defrance T, Casellas P (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92:3605-3615
33. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA(2002)Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2:69-82
34. Carrasco L, Smith AE (1976) Sodium ions and the shut-off of host cell protein synthesis by picornaviruses. Nature 264:807-809
35. Coates RA, Farewell VT, Raboud J, Read SE, MacFadden DK, Calzavara LM, Johnson JK, Shepherd FA, Fanning MM (1990) Cofactors of progression to acquired immunodeficiency syndrome in a cohort of male sexual contacts of men with human immunodeficiency virus disease. Am J Epidemiol 132:717-722
36. Coffey RG, Yamamoto Y, Snella E, Pross S (1996) Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem Pharmacol 52:743-751
37. Cohen S (1976) The 94-day cannabis study. Ann N Y Acad Sci 282:211-220
38. Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996) Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271:13175-13183
39. Crosby R, Diclemente RJ, Wingood GM, Harrington K, Davies SL, Hook EW, III, Oh MK (2002) Predictors of infection with Trichomonas vaginalis: A prospective study of low income African-American adolescent females. Sex Transm Infect 78:360-364
40. Croxford JL, Miller SD(2003) Immunoregulation of a viral model ofmultiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 111:1231-1240
41. Daaka Y, Klein TW, Friedman H(1995)Expressionof cannabinoid receptormRNAinmurine and human leukocytes. Adv Exp Med Biol 373:91-96
42. Daaka Y, Friedman H, Klein TW (1996) Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 276:776-783
43. Daaka Y, Zhu W, Friedman H, Klein TW (1997) Induction of interleukin-2 receptor alpha gene by delta-9-Tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor. DNA Cell Biol 16:301-309
44. De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M, Di Marzo V (1998) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95:8375-8380
45. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369:177-182
46. Derocq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Segui M, Casellas P (1998) The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425:419-425
47. Devane WA, Dysarz FA, III, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613
48. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
49. Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS (1996) The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study. Ann Epidemiol 6:283-289
50. Diaz S, Specter S, Coffey RG (1993) Suppression of lymphocyte adenosine 3':5'-cyclic monophosphate (cAMP) by delta-9-Tetrahydrocannabinol. Int J Immunopharmacol 15:523-532
51. Diaz S, Specter S, Vanderhoek JY, Coffey RG(1994)Theeffectof delta-9-Tetrahydrocannabinol on arachidonic acid metabolism in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 268:1289-1296
52. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92:3376-3380
53. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA (1992) Cannabinoid agonists stimulate both receptor-And non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42:838-845
54. Fischer-Stenger K, Updegrove AW, Cabral GA (1992) Delta-9- Tetrahydrocannabinol decreases cytotoxic T lymphocyte activity to herpes simplex virus type 1-infected cells. Proc Soc Exp Biol Med 200:422-430
55. Fischer-Stenger K, Dove Pettit DA, Cabral GA (1993) Delta-9- Tetrahydrocannabinol inhibition of tumor necrosis factor-Alpha: Suppression of post-Translational events. J Pharmacol Exp Ther 267:1558-1565
56. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R (2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a CB3 receptor. Eur J Pharmacol 461:27-34
57. Friedman H, Klein T, Specter S (1991) Immunosuppression by marijuana components. In: Ader R, FeltenDL, Cohen N(eds) Psychoneuroimmunology.Academic Press, San Diego, pp 931-953
58. Friedman H, Newton C, Klein TW (2003) Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 16:209-219
59. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
60. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Mechoulam R, Shohami E (1997) Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283:918-924
61. Garry RF, Bishop JM, Parker S, Westbrook K, Lewis G, Waite MR (1979) Na+ and K+ concentrations and the regulation of protein synthesis in Sindbis virus-infected chick cells. Virology 96:108-120
62. Garry RF, Ulug ET, Bose HR Jr. (1982) Membrane-mediated alterations of intracellular Na+ and K+ in lytic-virus-infected and retrovirus-Transformed cells. Biosci Rep 2:617-623
63. Goldsmith MA, Greene WC (1996) Interleukin-2 and interleukin-2 receptor. In: Thomas A (ed) The cytokine handbook. Academic Press, New York, pp 57-80
64. Griffin G, Tao Q, Abood ME (2000) Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. J Pharmacol Exp Ther 292:886-894
65. Gross A, Terraza A, Marchant J, Bouaboula M, Ouahrani-Bettache S, Liautard JP, Casellas P, Dornand J (2000) A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis. J Leukoc Biol 67:335-344
66. Gross G, Roussaki A, Ikenberg H, Drees N (1991) Genital warts do not respond to systemic recombinant interferon alpha-2a treatment during cannabis consumption. Dermatologica 183:203-207
67. Guarisco JL, Cheney ML, LeJeune FE Jr, Reed HT (1988) Isolated uvulitis secondary to marijuana use. Laryngoscope 98:1309-1312
68. Harkess J, Gildon B, Istre GR (1989) Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87. Am J Public Health 79:463-466
69. Herring AC, Koh WS, Kaminski NE (1998) Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-Active cannabinoid. Biochem Pharmacol 55:1013-1023
70. Hollister LE (1986) Health aspects of cannabis. Pharmacol Rev 38:1-20
71. Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27:429-436
72. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634
73. Howlett AC, Fleming RM(1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532-538
74. Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307-313
75. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
76. Jan TR, Rao GK, Kaminski NE (2002) Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. Mol Pharmacol 61:446-454
77. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE (1996) Attenuation of inducible nitric oxide synthase gene expression by delta-9-Tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol Pharmacol 50:334-341
78. Juel-Jensen BE (1972) Cannabis and recurrent herpes simplex. Br Med J 4:296
79. Kagen SL, Kurup VP, Sohnle PG, Fink JN (1983)Marijuana smoking and fungal sensitization. J Allergy Clin Immunol 71:389-393
80. Kaminski NE(1998)Regulation of thecAMPcascade, gene expression andimmune function by cannabinoid receptors. J Neuroimmunol 83:124-132
81. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736-742
82. Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK (1994) Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 48:1899-1908
83. Kaslow RA, Blackwelder WC, Ostrow DG, Yerg D, Palenicek J, Coulson AH, Valdiserri RO (1989) No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. A report from the Multicenter AIDS Cohort Study. JAMA 261:3424-3429
84. Kawakami Y, Klein TW, Newton C, Djeu JY, Dennert G, Specter S, Friedman H (1988a) Suppression by cannabinoids of a cloned cell line with natural killer cell activity. Proc Soc Exp Biol Med 187:355-359
85. Kawakami Y, Klein TW, Newton C, Djeu JY, Specter S, Friedman H (1988b) Suppression by delta-9-Tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-Activated killer cell activity. Int J Immunopharmacol 10:485-488
86. Killestein J, Hoogervorst EL, Reif M, Blauw B, Smits M, Uitdehaag BM, Nagelkerken L, Polman CH (2003) Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J Neuroimmunol 137:140-143
87. Klein TW, Friedman H (1990) Modulation of murine immune cell function by marijuana components. In:Watson R (ed) Drugs of abuse and immune function. CRC Press, Boca Raton, pp 87-111
88. Klein TW, Newton CA, Widen R, Friedman H (1985) The effect of delta-9-Tetrahydrocannabinol and 11-hydroxy-delta-9-Tetrahydrocannabinol on T-lymphocyte and Blymphocyte mitogen responses. J Immunopharmacol 7:451-466
89. Klein TW, Kawakami Y, Newton C, Friedman H (1991) Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 32:465-477
90. Klein TW, Newton C, Widen R, Friedman H (1993) Delta-9- Tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267:635-640
91. Klein TW, Friedman H, Specter S (1998a) Marijuana, immunity and infection. J Neuroimmunol 83:102-115
92. Klein TW, Newton C, Friedman H (1998b) Cannabinoid receptors and immunity. Immunol Today 19:373-381
93. Klein TW, Newton CA, Nakachi N, Friedman H (2000) Delta-9- Tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 164:6461-6466
94. Klein TW, Newton C, Snella E, Friedman H (2001)Marijuana, the cannabinoid system, and immunomodulation. In: Ader R, Felten DL, Cohen N (eds) Psychoneuroimmunology. Academic Press, San Diego, pp 415-432
95. Klykken PC, Smith SH, Levy JA, Razdan R, Munson AE (1977) Immunosuppressive effects of 8,9-epoxyhexahydrocannabinol (EHHC). J Pharmacol Exp Ther 201:573-579
96. Kusher DI, Dawson LO, Taylor AC, Djeu JY (1994) Effect of the psychoactive metabolite of marijuana, delta-9-Tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell Immunol 154:99-108
97. Lambert DM, DiPaolo FG, Sonveaux P, Kanyonyo M, Govaerts SJ, Hermans E, Bueb J, Delzenne NM, Tschirhart EJ (1999) Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440:266-274
98. Lawrence T, Willoughby DA, Gilroy DW (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2:787-795
99. Lee M, Yang KH, Kaminski NE(1995) Effects of putative cannabinoid receptor ligands, anandamide and 2-Arachidonyl-glycerol, onimmune function in B6C3F1mouse splenocytes. J Pharmacol Exp Ther 275:529-536
100. Lee SF, Newton C, Widen R, Friedman H, Klein TW(2001a)Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. Adv Exp Med Biol 493:223-228
101. Lee SF, Newton C, Widen R, Friedman H, Klein TW (2001b) Differential expression of cannabinoid CB(2) receptormRNAinmouseimmune cell subpopulations and following B cell stimulation. Eur J Pharmacol 423:235-241
102. Lefkowitz SS, Klager K(1978)Effectof delta-9-Tetrahydrocannabinol onin vitrosensitization of mouse splenic lymphocytes. Immunol Commun 7:557-566
103. Li X, Kaminski NE, Fischer LJ (2001) Examination of the immunosuppressive effect of delta-9-Tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int Immunopharmacol 1:699-712
104. Liau A, Diclemente RJ, Wingood GM, Crosby RA, Williams KM, Harrington K, Davies SL, Hook EW, III, Oh MK (2002) Associations between biologically confirmed marijuana use and laboratory-confirmed sexually transmitted diseases among African American adolescent females. Sex Transm Dis 29:387-390
105. Lozada F, Silverman S Jr, Migliorati CA, Conant MA, Volberding PA (1983) Oral manifestations of tumor and opportunistic infections in the acquired immunodeficiency syndrome (AIDS): Findings in 53 homosexual men with Kaposi's sarcoma. Oral Surg Oral Med Oral Pathol 56:491-494
106. Luo YD, Patel MK, Wiederhold MD, Ou DW(1992) Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins. Int J Immunopharmacol 14:49-56
107. Luthra YK, Esber HJ, Lariviere DM, Rosenkrantz H (1980) Assessment of tolerance to immunosuppressive activity of delta-9-Tetrahydrocannabinol in rats. J Immunopharmacol 2:245-256
108. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989) Delta-9-Tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73-81
109. Lynn AB, Herkenham M (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268:1612-1623
110. Marciano-Cabral F (1988) Biology of Naegleria spp. Microbiol Rev 52:114-133
111. Marciano-Cabral F, Ferguson T, Bradley SG, Cabral G (2001) Delta-9-Tetrahydrocannabinol (THC), the major psychoactive component ofmarijuana, exacerbates brain infection by Acanthamoeba. J Eukaryot Microbiol Suppl:4S-5S
112. Massi P, Fuzio D, Vigano D, Sacerdote P, Parolaro D (2000) Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)- Tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 387:343-347
113. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
114. McCoy KL, Gainey D, Cabral GA (1995) Delta-9-Tetrahydrocannabinol modulates antigen processing by macrophages. J Pharmacol Exp Ther 273:1216-1223
115. McCoy KL, Matveyeva M, Carlisle SJ, Cabral GA (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: Evidence for CB2 receptor participation. J Pharmacol Exp Ther 289:1620-1625
116. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS (2002) Delta(9)-Tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 302:451-465
117. Mechoulam R, Ben Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
118. Meyers WA, III, Heath RG (1979) Cannabis sativa: Ultrastructural changes in organelles of neurons in brain septal region of monkeys. J Neurosci Res 4:9-17
119. Miller JM Jr, Goodridge C (2000) Antenatal marijuana use is unrelated to sexually transmitted infections during pregnancy. Infect Dis Obstet Gynecol 8:155-157
120. Mishkin EM, Cabral GA (1985) Delta-9-Tetrahydrocannabinol decreases host resistance to herpes simplex virus type 2 vaginal infection in the B6C3F1 mouse. J GenVirol 66:2539-2549
121. Molina-Holgado F, Molina-Holgado E, Guaza C (1998) The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 433: 139-142
122. Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE (1979) Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infect Immun 23:670-674
123. Morahan PS, Morse SS, McGeorge MG(1980)Macrophage extrinsic antiviral activity during herpes simplex virus infection. J Gen Virol 46:291-300
124. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
125. Nahas GG, Morishima A, Desoize B (1977) Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc 36:1748-1752
126. Nakano Y, Pross SH, Friedman H (1992) Modulation of interleukin 2 activity by delta-9-Tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proc Soc Exp Biol Med 201:165-168
127. Newell GR, Mansell PW, Wilson MB, Lynch HK, Spitz MR, Hersh EM (1985) Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Prev Med 14:81-91
128. Newton C, Klein T, Friedman H (1998) The role of macrophages in THC-induced alteration of the cytokine network. Adv Exp Med Biol 437:207-214
129. Newton CA, Klein TW, Friedman H(1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-Tetrahydrocannabinol injection. Infect Immun 62:4015-4020
130. Noe SN, Nyland SB, Ugen K, Friedman H, Klein TW(1998) Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. Adv Exp Med Biol 437:223-229
131. Noe SN, Newton C, Widen R, Friedman H, Klein TW(2000) Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1mRNAexpression inmouse splenocytes. J Neuroimmunol 110:161-167
132. Nok AJ, Ibrahim S, Arowosafe S, Longdet I, Ambrose A, Onyenekwe PC, Whong CZ (1994) The trypanocidal effect of Cannabis sativa constituents in experimental animal trypanosomiasis. Vet Hum Toxicol 36:522-524
133. Paradise LJ, Friedman H (1993) Syphilis and drugs of abuse. Adv Exp Med Biol 335:81-87
134. Persaud NE, Klaskala W, Tewari T, Shultz J, Baum M(1999) Drug use and syphilis. Co-factors for HIV transmission among commercial sex workers in Guyana. West Indian Med J 48:52-56
135. Pross SH, Klein TW, Newton C, Smith J, Widen R, Friedman H (1990) Age-related suppression of murine lymphoid cell blastogenesis by marijuana components. Dev Comp Immunol 14:131-137
136. Pross SH, Nakano Y, Widen R, McHugh S, Newton CA, Klein TW, Friedman H (1992) Differing effects of delta-9-Tetrahydrocannabinol (THC) onmurine spleen cell populations dependent upon stimulators. Int J Immunopharmacol 14:1019-1027
137. Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126:2191-2202
138. Rachelefsky GS, Opelz G (1977) Normal lymphocyte function in the presence of delta-9-Tetrahydrocannabinol. Clin Pharmacol Ther 21:44-46
139. Ramarathinam L, Pross S, Plescia O, Newton C, Widen R, Friedman H (1997) Differential immunologic modulatory effects of tetrahydrocannabinol as a function of age. Mech Ageing Dev 96:117-126
140. Raz A, Goldman R (1976) Effect of hashish compounds on mouse peritoneal macrophages. Lab Invest 34:69-76
141. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Brelière JC, Le Fur GL (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650
142. Rosenkrantz H, Miller AJ, Esber HJ (1975) Delta-9-Tetrahydrocannabinol suppression of the primary immune response in rats. J Toxicol Environ Health 1:119-125
143. Sacerdote P, Massi P, Panerai AE, Parolaro D (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP 55,940 decreases the in vitro migration of macrophages in the rat: Involvement of both CB1 and CB2 receptors. J Neuroimmunol 109:155-163
144. Schatz AR, Kessler FK, Kaminski NE (1992) Inhibition of adenylate cyclase by delta-9-Tetrahydrocannabinol in mouse spleen cells: A potential mechanism for cannabinoidmediated immunosuppression. Life Sci 51:L25-L30
145. Schatz AR, Koh WS, Kaminski NE (1993) Delta-9-Tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26:129-137
146. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE (1997) Cannabinoid receptors CB1 and CB2: A characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142:278-287
147. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for binding of anandamide-Type compounds to the brain cannabinoid receptor. J Med Chem 40:659-667
148. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-Alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169-177
149. Showalter VM, Compton DR, Martin BR, Abood ME(1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999
150. Sidney S, Beck JE, Tekawa IS, Quesenberry CP, Friedman GD (1997) Marijuana use and mortality. Am J Public Health 87:585-590
151. Sinha D, Bonner TI, Bhat NR, Matsuda LA (1998) Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: Immunochemical characterization by fusion protein antibodies. J Neuroimmunol 82:13-21
152. Smith MS, Yamamoto Y, Newton C, Friedman H, Klein T (1997) Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila. Proc Soc Exp Biol Med 214:69-75
153. Smith SH, Harris LS, Uwaydah IM, Munson AE (1978) Structure-Activity relationships of natural and synthetic cannabinoids in suppression of humoral and cell-mediated immunity. J Pharmacol Exp Ther 207:165-170
154. Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293:136-150
155. Snella E, Pross S, Friedman H (1995) Relationship of aging and cytokines to the immunomodulation by delta-9-Tetrahydrocannabinol on murine lymphoid cells. Int J Immunopharmacol 17:1045-1054
156. Specter S, Lancz G, Westrich G, Friedman H(1991) Delta-9- Tetrahydrocannabinol augments murine retroviral induced immunosuppression and infection. Int J Immunopharmacol 13:411-417
157. Srivastava MD, Srivastava BI, Brouhard B(1998) Delta-9- Tetrahydrocannabinolandcannabidiol alter cytokine production by human immune cells. Immunopharmacology 40:179-185
158. Stefano GB, Bilfinger TV, Rialas CM, Deutsch DG (2000) 2-Arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol Res 42:317-322
159. Stohlman SA, Woodward JG, Frelinger JA (1982) Macrophage antiviral activity: Extrinsic versus intrinsic activity. Infect Immun 36:672-677
160. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831
161. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-Arachidonoylglycerol but not N-palmitoylethanolamine oranandamideis thephysiological ligandfor the cannabinoidCB2receptor.Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605-612
162. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, RothMD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42:71S-81S
163. Tindall B, Cooper DA, Donovan B, Barnes T, Philpot CR, Gold J, Penny R (1988) The Sydney AIDS Project: Development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med 18:8-15
164. Titishov N, Mechoulam R, Zimmerman AM (1989) Stereospecific effects of (-)-And (+)-7-hydroxy-delta-6-Tetrahydrocannabinol-dimethylheptyl on the immune system of mice. Pharmacology 39:337-349
165. Valk P, Verbakel S, Vankan Y, Hol S, Mancham S, Ploemacher R, Mayen A, Lowenberg B, Delwel R (1997) Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90:1448-1457
166. Vethanayagam D, Pugsley S, Dunn EJ, Russell D, Kay JM, Allen C (2000) Exogenous lipid pneumonia related to smoking weed oil following cadaveric renal transplantation. Can Respir J 7:338-342
167. Waksman Y, Olson JM, Carlisle SJ, Cabral GA(1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288:1357-1366
168. Wallace JM, Lim R, Browdy BL, Hopewell PC, Glassroth J, Rosen MJ, Reichman LB, Kvale PA (1998) Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 114:131-137
169. Warner JF, Dennert G (1982) Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo. Nature 300:31-34
170. Watzl B, Scuderi P, Watson RR (1991) Marijuana components stimulate human peripheral bloodmononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 13:1091-1097
171. Whitfield RM, Bechtel LM, Starich GH(1997) The impact of ethanol andMarinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. Alcohol Clin Exp Res 21:122-127
172. Wiley JL, Martin BR(2002)Cannabinoid pharmacology:implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121:57-63
173. Wiley JL, Martin BR (2003) Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471:185-193
174. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T(1994) Suppressionof experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28:209-214
175. Yebra M, Klein TW, Friedman H (1992) Delta-9-Tetrahydrocannabinol suppresses concanavalin A induced increase in cytoplasmic free calcium in mouse thymocytes. Life Sci 51:151-160
176. Zheng ZM, Specter S, Friedman H (1992) Inhibition by delta-9- Tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int J Immunopharmacol 14:1445-1452
177. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM (2000) Delta-9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165:373-380
178. Zhu W, Igarashi T, Qi ZT, Newton C, Widen RE, Friedman H, Klein TW (1993) Delta-9-Tetrahydrocannabinol (THC) decreases the number of high and intermediate affinity IL-2 receptors of the IL-2 dependent cell line NKB61A2. Int J Immunopharmacol 15:401-408
179. Zhu W, Newton C, Daaka Y, Friedman H, Klein TW (1994) Delta-9-Tetrahydrocannabinol enhances the secretion of interleukin 1 fromendotoxin-stimulatedmacrophages. J Pharmacol Exp Ther 270:1334-1339
180. Zhu W, Igarashi T, Friedman H, Klein TW (1995) Delta-9- Tetrahydrocannabinol (THC) causes the variable expression of IL2 receptor subunits. J Pharmacol Exp Ther 274:1001-1007
181. Zhu W, Friedman H, Klein TW (1998) Delta-9-Tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: Involvement of Bcl-2 and caspase-1. J Pharmacol Exp Ther 286:1103-1109
182. Zimmerman S, Zimmerman AM, Cameron IL, Laurence HL (1977) Delta-1-Tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacology 15:10-23